Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

NCT05393791 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

OTHER: Patient-specific adaptive therapy
DRUG: Abiraterone acetate
DRUG: Enzalutamide

Sponsor

Leiden University Medical Center

Collaborators

[object Object]
[object Object]